¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Malignant mast cell tumour"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® cell ÇÑ±Û ¼¼Æ÷
¼³¸í   
  »ý¸íü¸¦ ÀÌ·ç´Â ±¸Á¶Àû, ±â´ÉÀû ´ÜÀ§.
  
  ÇÙÀÇ À¯¹«¿¡ µû¶ó¼­ À¯ÇÙ¼¼Æ÷¿Í ¹«ÇÙ¼¼Æ÷·Î ³ª´­ ¼ö°¡ ÀÖ´Ù. ¹«ÇÙ¼¼Æ÷¶õ ÇÙÀÌ ¾ø´Â ¼¼Æ÷¸¦ ¸»ÇÑ´Ù. ÇÙÀ̶õ À¯ÀüÁ¤º¸¸¦ °¡Áö°í Àִ ¿°»öü¸¦ º¸°üÇϴ °÷Àε¥ ¹«ÇÙ¼¼Æ÷¿¡¼­´Â ¿°»öü°¡ ¼¼Æ÷¼Ó¿¡ ±×³É ³ëÃâµÇ¾î ÀÖ´Ù. ´ë°³ ¼¼Æ÷ ÇϳªÇϳª°¡ µ¶¸³µÈ »ý¸íüÀÇ ¿ªÇÒÀ» Çϴ ´Ü¼¼Æ÷»ý¹°·Î¼­ ¿ÜºÎȯ°æÀ¸·ÎºÎÅÍ ÀÚ½ÅÀ» º¸È£ÇÒ ¼ö Àִ °ß°íÇÑ ¼¼Æ÷º®À» °¡Áö°í ÀÖ´Ù. À¯ÇÙ¼¼Æ÷¶õ ÇÙÀ» °¡Áö°í À־ À¯ÀüÁ¤º¸°¡ Àִ ¿°»öü°¡ ¼¼Æ÷ÀÇ ´Ù¸¥ ºÎºÐ°ú ±¸ºÐµÇ¾î ÇÙ¼Ó¿¡ µé¾îÀÖ´Ù. ¼¼Æ÷¼Ó¿¡¼­ ÇÙ¿ÜÀÇ ºÎºÐ(À̸¦ ¼¼Æ÷ÁúÀ̶ó ÇÑ´Ù)¿¡´Â ¿©·¯ °¡Áö ¼¼Æ÷ÀÇ ¼Ò±â°üÀÌ À־ ¼¼Æ÷ÀÇ ´Ù¾çÇÑ ±â´ÉÀ» ºÐ´ãÇÑ´Ù.
  
  ¢ÂÀ¯ÇÙ¼¼Æ÷ÀÇ ±âº» ±¸Á¶
  
  1.¼¼Æ÷¸·-¼¼Æ÷¸¦ µÑ·¯½Î¼­ ÁÖÀ§È¯°æ°ú ºÐ¸®ÇÏ¿© ¼¼Æ÷ÀÇ ³»È¯°æÀ» À¯ÁöÇÑ´Ù.
  
  2.ÇüÁú³»¼¼¸Á(endoplasmic reticulum)-´ÜÀ§¸·À¸·Î µÑ·¯½×¿© Àִ ºÒ±ÔÄ¢ÇÑ ¸Á»ó±¸Á¶ÀÌ´Ù. ÀÌ ¸Á»ó±¸Á¶ÀÇ ³»ºÎ¸¦ ¼Ò°­, ¼ÒÁ¶¶ó°í ºÎ¸¥´Ù. ¿©±â¿¡´Â Ç¥¸éÀÌ ¸Å²öÇÑ ¹«°ú¸³ÇüÁú³»¼¼¸Á°ú Ç¥¸éÀÌ ºÒ±ÔÄ¢ÇÑ °ú¸³ÇüÁú³»¼¼¸ÁÀÇ µÎ °¡Áö°¡ ÀÖ´Ù. °ú¸³ÇüÁú³»¼¼¸ÁÀÇ °æ¿ì´Â Ç¥¸é¿¡ ´Ü¹éÁúÀ» ÇÕ¼ºÇϴ ¸®º¸¼ØÀ̶ó´Â °ÍÀÌ ºÎÂøµÇ¾î ÀÖ´Ù. À̰÷Àº ÁַΠ¼¼Æ÷¹ÛÀ¸·Î ºÐºñÇÒ ´Ü¹éÁúÀ» ÇÕ¼ºÇϴ Àå¼ÒÀÌ´Ù. ¹«°ú¸³ÇüÁú³»¼¼¸ÁÀº Ç¥¸é¿¡ ¸®º¸¼ØÀÌ ºÎÂøµÇ¾î ÀÖÁö ¾ÊÀº °ÍÀ» ¸»Çϸç, À̰÷¿¡¼­´Â ÁÖ·Î ÇØµ¶ÀÛ¿ë, ±Û¸®ÄÚ°ÕÀÇ ÇÕ¼º, ½ºÅ×·ÎÀ̵åÈ£¸£¸óÀÇ ÇÕ¼º µîÀÌ ÀϾ´Ù.
  
  3.¸®º¸¼Ø-´Ü¹éÁúÀ» ÇÕ¼ºÇϴ ¿ªÇÒÀ» Çϴ °÷ÀÌ´Ù.À̰ÍÀº ¼¼Æ÷Áú¿¡ Á¸ÀçÇϴ ÀÚÀ¯¸®º¸¼Ø°ú °ú¸³ÇüÁú³»¼¼¸Á¿¡ ºÎÂøÀÌ µÇ¾î Á¸ÀçÇϴ ºÎÂø¸®º¸¼ØÀÇ µÎ °¡Áö·Î ³ª´«´Ù. ÀÚÀ¯¸®º¸¼ØÀº ÁַΠ¼¼Æ÷³»¿¡¼­ ÇÊ¿äÇÑ ´Ü¹éÁúÀ» ¸¸µå´Â ¿ªÇÒÀ» Ç졒ʼÎÂø¸®º¸¼ØÀº ¼¼Æ÷¹ÛÀ¸·Î ºÐºñÇÒ ´Ü¹éÁúÀ» ¸¸µå´Â ¿ªÇÒÀ» ÇÑ´Ù.
  
  4.°ñÁöÀåÄ¡(Golgi apparatus)-ÇÙÁÖÀ§¿¡ ºÐÆ÷Çϴ ³³ÀÛÇØÁø ÁָӴϸð¾çÀÇ °ÍÀÌ ÁßøµÇ¾î Çü¼ºµÈ ÃþÆÇ ¸ð¾çÀÇ ±¸Á¶¹°·Î °ú¸³ÇüÁú³»¼¼¸Á¿¡¼­ »ý¼ºµÇ¾î ¿ÜºÎ·Î ºÐºñµÉ ´Ü¹éÁúÀ» ¸ð¾Æ¼­ ³óÃà, Æ÷ÀåÇÏ¿© °ú¸³À» ¸¸µå´Â ¿ªÇÒÀ» ÇÑ´Ù.
  
  5.»ç¸³Ã¼(mitochondria)-±¸Çü, ³­ÇüÀÇ ±ä ¸·´ë±â ¸ð¾çÀ¸·Î Å©±â°¡ ´Ù¾çÇÑ ±¸Á¶¹°. »ý¹°Ã¼ÀÇ ¿¡³ÊÁö ÀúÀå¹°ÁúÀΠATP¸¦ »ý»êÇϴ ¿ªÇÒÀ» ÇÑ´Ù. ¶Ç ¼¼Æ÷¿Í ´Ù¸¥ ÀڽŸ¸ÀÇ À¯ÀüÁ¤º¸¸¦ °¡Áø DNA, RNA¸¦ °¡Áö°í ÀÖ´Ù. ¸ð¾ç, Å©±â°¡ ¼¼±Õ°ú ºñ½ÁÇϸç ÀÚüÁõ½Ä¼º µî µ¶¸³µÈ »ý¸íü·Î¼­ ÇÊ¿äÇÑ ¿ä°ÇÀ» °®Ãß°í À־ ¼¼Æ÷¿Í °ø»ý°ü°è¸¦ °¡Áø µ¶¸³µÈ ¼¼Æ÷·Î »ý°¢Çϰí ÀÖ´Ù.
  
  6.¿ëÇØ¼Òü(lysosome)-ÀÛÀº ±¸ÇüÀÇ ¼Òü·Î ¿©·¯ °¡Áö ºÐÇØÈ¿¼Ò¸¦ °¡Áø´Ù. ¼¼Æ÷¿Ü°è¿¡¼­ µé¾î¿Â ¹°Áú°ú °áÇÕÇÏ¿© ±× ¹°ÁúµéÀ» ¿ëÇØÇϴ ¿ªÇÒÀ» Çϰí, ¿À·¡µÈ ¼¼Æ÷¼Ò±â°üµéÀ» Á¦°ÅÇϴ ¿ªÇÒµµ ÇÑ´Ù.
  
  7.¼¼Æ÷ÇÙ(nucleus)-±¸Çü, ³­ÇüÀ¸·Î ¼¼Æ÷ÀÇ Á߽ɿ¡ À§Ä¡ÇÑ´Ù. ÇÙ³»¿¡´Â À¯ÀüÁ¤º¸°¡ Àִ ¹°ÁúÀΠ¿°»öü°¡ Á¸ÀçÇÑ´Ù.
  
  8.Á߽ɼÒü(centrosome)-ÇÙÁÖÀ§¿¡ Á¸ÀçÇϸ鼭 ÇÙÀÇ ºÐ¿­½Ã¿¡ ¾çÂÊÀÇ ¿°»öü¸¦ ´ç±â´Â ÀÛÀº ¼¶À¯¸¦ ¸¸µå´Â ¿ªÇÒÀ» Çϴ °÷.
  
  ¼¼Æ÷
¿µ¹® cell-mediated immunity ÇÑ±Û ¼¼Æ÷¸Å°³¸é¿ª
¼³¸í   
  ¸é¿ªÀ̶õ ½Åü¸¦ ¿ÜºÎÀÇ ¹°Áú·ÎºÎÅÍ º¸È£Çϴ ÇàÀ§¸¦ ¸»ÇÑ´Ù. ¿©±â¿¡´Â Æ¯ÀÌÀû ¸é¿ª°ú ºñƯÀÌÀû ¸é¿ªÀÇ µÎ °¡Áö°¡ ÀÖ´Ù.
  
  ºñƯÀÌÀû ¸é¿ªÀ̶óÇÔÀº Æ¯Á¤ÇÑ ¹°Áú¿¡ °ü°èÇϴ ¸é¿ªÀÌ ¾Æ´Ï¶ó Æ¯Á¤ ´ë»óÀÌ ¾øÀÌ ¸ðµç ¿ÜºÎ ¹°Ã¼¿¡ ÀÛ¿ëÇÒ ¼ö Àִ ¸é¿ªÀ» ¸»ÇÑ´Ù. ¿©±â¿¡´Â ¼Òº¯ÀÇ È帧, ´«¹°ÀÇ È帧, ÇǺÎÀÇ ºñÅõ°ú¼º µîÀÇ ±â°èÀûÀΠ°Íµµ Æ÷ÇԵǰí ÇǼӿ¡ µ¹¾Æ´Ù´Ï´Â ¼¼Æ÷ Áß¿¡¼­ ºñƯÀÌÀûÀ¸·Î ¿ÜºÎÀÇ ¹°ÁúÀ» Æ÷½ÄÇϴ ¼¼Æ÷µé(¿¹¸¦ µé¸é Å«Æ÷½Ä¼¼Æ÷(macrophage)ÀǠȰµ¿µµ Æ÷ÇÔÀÌ µÈ´Ù. ¼¼Æ÷¸Å°³¸é¿ªÀ̶õ Æ¯ÀÌÇÑ ¹°ÁúÀ» °¨ÁöÇÒ ¼ö Àִ ¼¼Æ÷¸¦ »ý¼ºÇϰԠÇÏ¿© ±×°ÍÀ¸·Î ÇÏ¿©±Ý ±× ¹°ÁúÀ» Æ÷½ÄÇϰԠÇϴ °ÍÀ» ¸»ÇÑ´Ù.
¿µ¹® nerve cell ÇÑ±Û ½Å°æ¼¼Æ÷
¼³¸í   
  ½Å°æ¼¼Æ÷´Â ¿Ã¹Ù¸¥ ½Å°æÀü´ÞÀ» À§ÇÑ °¢ ºÎºÐº°·Î ³ª´µ¾îÁ® ÀÖ´Ù. ½Å°æ¼¼Æ÷¿¡¼­´Â ÀüÇØÁ®¿À´Â ÀÚ±ØÀ» Àü±âÀûÀΠ½ÅÈ£·Î ¹Ù²î¾î º¸³»°Å³ª ¹Þ°Ô µÈ´Ù. ÀÌ·± Àü±âÀûÀΠÇö»óÀº °¢ ½Å°æ¼¼Æ÷³»¿¡ Á¸ÀçÇϴ °¢ ÀÌ¿Âä³Î(ion channel: ionÀ̶õ ³ªÆ®·ý, Ä®·ý µîÀ» ÁöĪÇϴ ¸»µé·Î½á, À̵éÀÌ ¼¼Æ÷¸·¿¡ ÀÇÇØ ³ª´µ¾îÁú ¶§ »ý±â´Â Àü¾ÐÂ÷°¡ Àü±âÀû ÀÚ±ØÀ» ÀÏÀ¸Å°°í À¯ÁöÇϴµ¥ °áÁ¤ÀûÀΠ¿ªÇÒÀ» ÇÑ´Ù)µéÀÇ ÀÛ¿ë¿¡ ÀÇÇØ ÀÌ·ç¾îÁö°Ô µÈ´Ù.
¿µ¹® glia cell ÇÑ±Û ¾Æ±³¼¼Æ÷
¼³¸í   
  ½Å°æ¼¼Æ÷ »çÀÌ¿¡¼­ ±×¹°±¸Á¶¸¦ ÀÌ·ç¸ç À̸¦ ÁöÁöÇϴ Á¶Á÷. ½Å°æ¾Æ±³¼¼Æ÷´Â ½Å°æ¸ð¼¼Æ÷¿Í °¥¶óÁø ¾Æ±³¸ð¼¼Æ÷°¡ ´Ù½Ã ¿©·¯ ÇüÅ·ΠºÐÈ­-¼ºÀåÇÑ °ÍÀÌ´Ù. ³ú½ÇÀ̳ª Ã´¼öÁ߽ɰüÀÇ º®À» µ¤°í ¿øÁÖ»ó ¶Ç´Â ÀÔ¹æÇüÀ̸ç, Ãʱ⿡´Â À¯¸®¸é¿¡ ¼¶¸ð°¡ ÀÖ´Ù. ´ëÇü¼¼Æ÷´Â º°³ú½Ç¸·¼¼Æ÷´Â ¾Æ±³¼¼Æ÷¶ó°í Çϸç, ½Å°æ¼¼Æ÷³ª ½Å°æ¼¶À¯ »çÀÌ¿¡ »êÀçÇÑ´Ù. ±× ¿Ü¿¡ Èñ¼Òµ¹±â¾Æ±³¼¼Æ÷µµ Æ÷ÇԵȴÙ.
¿µ¹® reserve cell ÇÑ±Û ¿¹ºñ¼¼Æ÷
¼³¸í   
  ÀϹÝÀûÀ¸·Î »óÇÇÁ¶Á÷¿¡¼­ À̹̠ÀÖ´ø »óÇǼ¼Æ÷°¡ ¼Õ»óÀ» ¹Þ¾Æ »ç¸êÇϸ頸ŲãÁö´Â ±× ¹Ø¿¡ Àִ ¹ÌºÐÈ­¼¼Æ÷ ¿¹¸¦ µé¸é, ±â°üÁö ³»Ç¥¸éÀ» µ¤´Â ÁßÃþ ¿øÁÖ »óÇÇÀÇ ±âÀú¿¡ Àִ ÀÛÀº ¹ÌºÐÈ­ »óÇÇ ¼¼Æ÷.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • malignant mesothelioma
    ¾Ç¼ºÁßÇÇÁ¾
  • malignant myopia
    ¾Ç¼º±Ù½Ã
  • malignant smallpox
    ¾Ç¼º¸¶¸¶
  • malignant teratoma
    ¾Ç¼º±âÇüÁ¾
  • malignant transformation
    ¾Ç¼ºÀüȯ
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • neuroleptic malignant syndrome
    ½Å°æÀÌ¿ÏÁ¦¾Ç¼ºÁõÈıº
  • acantholytic cell
    °¡½Ã¼¼Æ÷ºÐ¸®¼¼Æ÷
  • angioimmunoblastic T-cell lymphoma
    Ç÷°ü¸é¿ª¸ð±¸T¼¼Æ÷¸²ÇÁÁ¾
  • annular elastotic giant cell granuloma
    °í¸®Åº·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾, ȯ»óź·Â¼¶À¯°Å´ë¼¼Æ÷À°¾ÆÁ¾
  • accessory cell
    º¸Á¶¼¼Æ÷, µ¡¼¼Æ÷
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • basket cell
    ¹Ù±¸´Ï¼¼Æ÷
  • basophilic cell
    È£¿°±â¼¼Æ÷
  • beta cell
    º£Å¸¼¼Æ÷
  • bipolar cell
    µÎ±Ø¼¼Æ÷
  • blood cell
    Ç÷¾×¼¼Æ÷, Ç÷±¸
  • ethmoidal cell
    ¹úÁý»À¹úÁý
  • eukaryotic cell
    ÁøÇÙ¼¼Æ÷
  • goblet cell
    ¼úÀܼ¼Æ÷
  • hair cell
    Åм¼Æ÷
  • inflammatory cell
    ¿°Áõ¼¼Æ÷
  • killer cell
    »ìÇØ¼¼Æ÷
  • Kupffer's cell
    º°Å«Æ÷½Ä¼¼Æ÷, ÄíÆÛ¼¼Æ÷
  • mesenchymal cell
    Áß°£¿±¼¼Æ÷
  • mesothelial cell
    ÁßÇǼ¼Æ÷
  • mother cell
    ¸ð¼¼Æ÷, ¾î¹Ì¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • malignant hidradenoma
    ¾Ç¼º¶¡»ùÁ¾
  • malignant hypertension
    ¾Ç¼º°íÇ÷¾Ð
  • malignant hyperthermia
    ¾Ç¼º°í¿­
  • malignant fibrous histiocytoma
    ¾Ç¼º¼¶À¯Á¶Á÷±¸Á¾
  • malignant progressive histiocytoma
    ¾Ç¼ºÁøÇàÁ¶Á÷±¸Á¾
  • malignant
    ¾Ç¼º-
  • malignant acanthosis nigricans
    ¾Ç¼ºÈæ»ö°¡½Ã¼¼Æ÷Áõ
  • malignant melanoma
    ¾Ç¼ºÈæ»öÁ¾
  • malignant myopia
    (¢¡degenerative myopia) º¯¼º±Ù½Ã
  • malignant smallpox
    ¾Ç¼º¸¶¸¶
  • malignant teratoma
    ¾Ç¼º±âÇüÁ¾
  • malignant transformation
    ¾Ç¼º¼¼Æ÷Àüȯ
  • malignant tumor
    ¾Ç¼ºÁ¾¾ç
  • malignant chondroid syringoma
    ¾Ç¼º¿¬°ñ¶¡°üÁ¾
  • neuroleptic malignant syndrome
    Ç×Á¤½Åº´¾à¹°¾Ç¼ºÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • B cell growth factor
    B ¼¼Æ÷¼ºÀåÀÎÀÚ
  • B cell growth factor (BCGF)
    B¼¼Æ÷ Áõ½ÄÃËÁøÀÎÀÚ
  • B cell hybridoma
    B¼¼Æ÷ ÇÏÀ̺긮µµ¸¶
  • B cell lymphoma
    B¼¼Æ÷¸²ÇÁÁ¾
  • B cell stimulating factor (BSF)
    B¼¼Æ÷ ÀÚ±ØÀÎÀÚ
  • B cell study
    B ¼¼Æ÷°Ë»ç
  • B cell/lymphocyte
    B ¼¼Æ÷/¸²ÇÁ±¸
  • B-cell
    ºñ ¼¼Æ÷
  • C-cell
    C ¼¼Æ÷
  • CD4+ cell
    CD4+ ¼¼Æ÷
  • Cell adhesion molecules
    ¼¼Æ÷À¯ÂøºÐÀÚ
  • Chinese hamster ovary tumor cell
    Áß±¹ÇÔ½ºÅÍ ³­¼Ò¼¼Æ÷, CHO¼¼Æ÷
  • Graham cell
    ±×¶óÇÔ¼¼Æ÷
  • Granulosa cell
    °ú¸³¸·¼¼Æ÷(Î¨Ø£Ø¯á¬øà)
  • Granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç(Î¨Ø£Ø¯á¬øàðþåË)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mast atrophy
    À¯¼±À§Ãà(¡­ê×õê).
  • malignant baloon cell nevus
    ¾Ç¼º dz¼±¼¼Æ÷ ¸ð¹Ý
  • malignant cell
    ¾Ç¼º¼¼Æ÷(ç÷àõá¬øà).
  • malignant clear cell hidradenoma
    ¾Ç¼º Åõ¸í¼¼Æ÷ ÇѼ±Á¾
  • borderline malignant epithelial ovarian neoplasms
    °æ°è¼º »óÇǼº ³­¼ÒÁ¾¾ç
  • fibrous histiocytoma,malignant
    ¾Ç¼º¡­ (äÂàõ¡­)
  • granuloma, malignant
    ¾Ç¼ºÀ°¾ÆÁ¾
  • histiocytoma,malignant fibrous
    Á¶Á÷±¸Á¾, ¾Ç¼º ¼¶À¯¼º
  • histiocytosis,malignant
    ¾Ç¼º
  • hypertension,malignant
    ¾Ç¼º(äÂàõ)
  • jaw,nonodontogenic malignant tumor
    ºñÄ¡¾Æ¼º ¾Ç¼ºÁ¾¾ç (¡­ äÂàõðþåË)
  • lues maligna => malignant syphilis
    ¾Ç¼º(äÂàõ)¸Åµ¶
  • malignant
    ¾Ç¼º(ç÷àõ)ÀÇ.
  • malignant
    ¾Ç¼º(ç÷àõ)ÀÇ
  • malignant
    ¾Ç¼ºÀÇ, (ºÏ) ¾Ç¼ºÀÇ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷
  • Supporting cell [Type II glomus cell]
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁö¼¼Æ÷(Á¦2Çü»ç±¸¼¼Æ÷)
  • Striated muscle cell
    °¡·Î¹«´Ì±ÙÀ°¼¼Æ÷
    [¿¾ ¿ë¾î] Ⱦ¹®±Ù¼¼Æ÷
  • Sensory epithelial cell
    °¨°¢»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] °¨°¢»óÇǼ¼Æ÷
  • Cortical endocrine cell
    °ÑÁú³»ºÐºñ¼¼Æ÷
    [¿¾ ¿ë¾î] ÇÇÁú³»ºÐºñ¼¼Æ÷
  • Nodal cell
    °áÀý¼¼Æ÷
    [¿¾ ¿ë¾î] °áÀý¼¼Æ÷
  • Granule cell
    °ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³¼¼Æ÷
  • Granular lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³ÃþȲü¼¼Æ÷
  • Granulosa lutein cell
    °ú¸³ÃþȲ(»ö)ü¼¼Æ÷
    [¿¾ ¿ë¾î] °ú¸³ÃþȲü¼¼Æ÷
  • Myoepithelial cell
    ±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ±Ù»óÇǼ¼Æ÷
  • Myoid cell layer
    ±ÙÀ°¼¶À¯¸ð¼¼Æ÷Ãþ
    [¿¾ ¿ë¾î] ±Ù¼¶À¯¾Æ¼¼Æ÷Ãþ
  • Satellite cell of skeletal muscle
    ±ÙÀ°À§¼º¼¼Æ÷
    [¿¾ ¿ë¾î] ±ÙÀ§¼º¼¼Æ÷
  • Sebaceous cell
    ±â¸§»ù¼¼Æ÷
    [¿¾ ¿ë¾î] ÇÇÁö¼¼Æ÷
  • Centroacinar cell
    ²Ê¸®Á߽ɼ¼Æ÷
    [¿¾ ¿ë¾î] ¼±Æ÷Á߽ɼ¼Æ÷
  • Thecal cell
    ³­Æ÷¸·¼¼Æ÷
    [¿¾ ¿ë¾î] ³­Æ÷¸·¼¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cell differentiation
    ¼¼Æ÷ºÐÈ­(á¬øàÝÂûù)
  • cell envelope
    ¼¼Æ÷(á¬øà)½Î°³
  • cell factor
    ¼¼Æ÷ÀÎÀÚ(á¬øàì×í­)
  • cell fractionation
    ¼¼Æ÷ºÐȹȭ(á¬øàÝÂüñûù)
  • cell-free amino acid incorporating system
    ¹«¼¼Æ÷(Ùíá¬øà) ¾Æ¹Ì³ë»ê ÆíÀÔ(øºìý)¾¾½ºÅÛ
  • cell-free extract
    ¹«¼¼Æ÷ÃßÃâ¹°(Ùíá¬øàõÎõóÚª)
  • cell-free protein synthesis
    ¹«¼¼Æ÷´Ü¹éÁúÇÕ¼º(Ùíá¬øàÓ±ÛÜòõùêà÷)
  • cell-free system
    ¹«¼¼Æ÷(Ùíá¬øà)½Ã½ºÅÛ
  • cell fusion
    ¼¼Æ÷À¶ÇÕ(á¬øàë×ùê)
  • cell hybridization
    ¼¼Æ÷(á¬øà) Æ¢±âÇü¼º(û¡à÷)
  • cell line
    ¼¼Æ÷ÁÖ(á¬øàñ»)
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª(á¬øàØÚË¿Øóæ¹)
  • cell membrane
    ¼¼Æ÷¸· (á¬øàØ¯)
  • cell strain
    ¼¼Æ÷ÁÖ(á¬øàñ»)
  • cell wall
    ¼¼Æ÷º®(á¬øàÛú)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • blast cell
    ¸ð¼¼Æ÷
  • blood cell
    Ç÷±¸
  • cell
    ¼¼Æ÷, ¹úÁý, ºÀ¼Ò, °ÇÀüÁö
  • chromaffin cell
    Å©·Òģȭ¼¼Æ÷
  • clear cell
    Åõ¸í ¼¼Æ÷
  • columnar cell
    ¿øÁÖ¼¼Æ÷
  • cuboidal cell
    ÀԹ漼Æ÷
  • daughter cell
    µþ¼¼Æ÷, ³¶¼¼Æ÷
  • dendrite cell
    ³ª¹«°¡Áö¼¼Æ÷, ¼ö»ó¼¼Æ÷
  • differentiated cell
    ºÐÈ­¼¼Æ÷
  • diffuse large cell lymphoma
    ¹Ì¸¸¼º Å«¼¼Æ÷ÀÓÆÄÁ¾
  • ependymal cell
    ³ú½Ç¸· ¼¼Æ÷, »óÀǼ¼Æ÷
  • fat cell
    Áö¹æ¼¼Æ÷
  • foam cell
    Æ÷¸» ¼¼Æ÷
  • follicular cell
    ¼ÒÆ÷¼¼Æ÷, ³­Æ÷¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CTMC connective tissue mast cell
CYM chymase, mast cell
IMC indigent medical care; information-memory-concentration [test]; interdigestive migrating contraction...
MCGF mast cell growth factor
MDT mast [cell] degeneration test; mean dissolution time; median detection threshold; multidisciplinary ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MGF Mast cell growth factor
MCT mast cell tumor
MMCP Mouse mast cell protease
MMC Mucosal mast cell
RMCP-II Rat mast cell protease II
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • malignant hyperthermia
    ¾Ç¼º °í¿­Áõ, ¾Ç¼º °í¿­
    ¸¶Ãë Áß¿¡ °©ÀÚ±â °í¿­À» ³»°í »ç¸Á·üÀÌ ±ØÈ÷ ³ôÀº ÁõÈıº¿¡ ´ëÇÏ¿© À̸§ÀÌ ºÙ¿©Áø °ÍÀÌ´Ù. Áõ»óÀº È£ÈíÀ̳ª ¸Æ¹ÚÀÌ »¡¶óÁö°í ü¿ÂÀº 5ºÐ¿¡ 1¡É Á¤µµÀÇ ¼Óµµ·Î 42¡É¿¡³ª ´ÞÇÑ´Ù. µ¿½Ã¿¡ ±ÙÀÇ °æÁ÷À̳ª °ú±äÀåÀÌ »ý±â°í ´ë»ç¼º ¹× È£Èí¼º »êÁõ, °íÄ®·ýÇ÷ÁõÀÌ ³ªÅ¸³­´Ù. ±Ù°æÁ÷¼º À§Ãà, À¯ÀüÀÚ ÀÎÀÚ
  • malignant hyperthermia syndrome
    ¾Ç¼º °í¿­ ÁõÈıº
  • malignant lesion
    ¾Ç¼º º´¼Ò
  • malignant melanoma
    ¾Ç¼º Èæ»öÁ¾
    1. ¿ÜÀ½¿¡ »ý±â´Â °¡Àå Áß¿äÇÑ º´º¯ÀÎ Á¾¾çÀÇ ÀÏÁ¾À¸·Î ¿ÜÀ½ÀÇ ¾Ç¼º Èæ»öÁ¾Àº µå¹°°í, ¿©¼º¿¡¼­ °üÂûµÇ´Â Èæ»öÁ¾ÀÇ 2%°¡ ¿ÜÀ½¿¡¼­ ¹ß»ýÇÑ´Ù. 2. »ö¼Ò ¼¼Æ÷¿¡ »ý±ä ¾Ç¼º Á¾¾ç. 3. Ç¥ÇǼº Èæ»ö±¸¿Í ±× Àü±¸Ã¼·ÎºÎÅÍ ¹ß»ýÇÏ´Â ´ë´ÜÈ÷ ¾Ç¼ºÀÎ Á¾¾çÀÌ´Ù. ¸ðµç ¾Ç¼º Á¾¾ç Áß 1%°¡ ¾Ç¼º Èæ»öÁ¾ÀÌ´Ù. ÀÌÁß 90%´Â ¿ÜÇÇ¿¡ ³ªÅ¸³ª°í 10%´Â ÇǺΠ¿Ü¿¡ ³ªÅ¸³­´Ù. ¸ðµç ¾Ç¼º Èæ»öÁ¾ Áß 1%´Â ±¸°­ ³»¿¡¼­ ¹ß»ýÇÑ´Ù. ¹ß»ýÀ²ÀÌ Áõ°¡µÇ´Â °Íó·³ º¸ÀÌ´Â ÀÌ·± Á¾¾çÀÇ Æ¯È÷ ³ª»Û Á¡Àº ¸²ÇÁ ¼øÈ¯°ú Ç÷¾× ¼øÈ¯À» ÅëÇØ ºü¸£°Ô ÀüÀ̵Ǵ °ÍÀÌ´Ù.
  • malignant mesenchymoma
    ¾Ç¼º ³»¹è¿±Á¾
  • malignant myopia
    ¾Ç¼º ±Ù½Ã
    Ã༺ ±Ù½Ã·Î¼­ ¾ÈÃàÀåÀÌ ±¼Àý·Â¿¡ ºñÇØ ³Ê¹« ±æ¾î ÆòÇà ±¤¼±ÀÌ ¸Á¸· ¾Õ¿¡ ÃÊÁ¡À» ¸ÎÀ¸¹Ç·Î ¼±¸íÇÏÁö ¾ÊÀº »óÀ» ¸Î°Ô µÈ´Ù. °úµµÇÑ Á¶Àý ¹× ´« ¸ðÀ½, ½Ã½Å°æ À¯µÎÀÇ ºÎÁ¾, ³»ºÐºñ ÀÌ»ó, Æí½Ä µîÀÌ ¿øÀÎÀ̶ó°í ÇÏ´Â ÁÖÀåµµ ÀÖÀ¸³ª ºÐ¸íÄ¡ ¾Ê´Ù.
  • malignant neoplasm
    ¾Ç¼º ½Å»ý¹°
  • malignant oxyphilic adenoma
    ¾Ç¼º È£»ê¼º ¼±Á¾
  • malignant pleomorphic adenoma
    ¾Ç¼º ´ÙÇü¼º ¼±Á¾
  • malignant salivary gland tumor
    ¾Ç¼º Ÿ¾×¼± Á¾¾ç
  • malignant tumor
    ¾Ç¼º Á¾¾ç
    Á¤»óÀûÀÎ Á¶Á÷ ¼¼Æ÷°¡ °¢Á¾ ¹°¸®Àû, È­ÇÐÀû, »ý¹°ÇÐÀûÀÎ ¾Ï¿ø¼º ¹°ÁúÀÇ ÀÛ¿ë ¶Ç´Â ¿äÀο¡ ÀÇÇØ µ¹¿¬º¯À̸¦ ÀÏÀ¸ÄѼ­ Çü¼ºµÇ´Â Á¾¾ç ¹«Á¦ÇÑÀÇ ¼¼Æ÷ ºÐ¿­·Î ¸Å¿ì ¿Õ¼ºÇÏ°Ô Áõ½ÄÇÏ¿© ÁÖÀ§ Á¶Á÷À» ÆÄ±«, ħ½ÄÇÑ´Ù. ¶Ç ¾î¶² È­Çй°ÁúÀ» ³»¾î ÁÖÀ§ÀÇ Á¶Á÷ ¼¼Æ÷¸¦ Ä§ÇØÇÒ »Ó¸¸ ¾Æ´Ï¶ó, Ç÷°ü ¹× ¸²ÇÁ°üÀ» µû¶ó ÀüÀÌÇÏ¿© Àü½ÅÀÇ ¾Ç¾×ÁúÀ» ¾ß±â½ÃÄÑ Á×À½ÀÇ À§ÇèÀ» ÃÊ·¡ÇÑ´Ù. »óÇǼºÀÎ °ÍÀ» ¾ÏÁ¾À̶ó Çϰí, ºñ»óÇǼºÀÎ °ÍÀ» À°Á¾À̶ó ÇÑ´Ù.
  • non-malignant
    ºñ¾Ç¼º
  • nonodontogenic malignant tumor jaw
    ºñÄ¡¾Æ¼º ¾Ç¼º Á¾¾ç
  • rare malignant granulomatoses
    Èñ±ÍÇÑ ¾Ç¼º À°¾ÆÁ¾Áõ
  • ulcerated malignant tumor
    ±Ë¾ç¼º ¾Ç¼º Á¾¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
granular cell tumour Unusual tumour affecting any site of the body, but most often encountered in the head and neck. Considerable debate has surrounded the histogenesis of this neoplasm; however, it is considered to be a myoblastoma of, usually, a benign nature. It affects women more often than men. When it develops beneath the epidermis or mucous membrane, it can lead to proliferation of the squamous cells and mimic squamous cell carcinoma.
(12 Dec 1998)
granulosa cell tumour An ovarian tumour originating in the cells of the primordial membrana granulosa of the graafian follicle. It may be associated with excessive production of estrin, inducing endometrial hyperplasia with menorrhagia. It can be benign or malignant. It is soft, solid, white or yellow, and consists of small round cells sometimes enclosing call-exner bodies. Larger lipid-containing cells may be present. Granulosa cell tumours are seen in women of all ages. Treatment depends on the age of the patient and the extent of the disease.
(12 Dec 1998)
hilar cell tumour of ovary A small benign masculinizing ovarian tumour derived from hilar cells, which resemble Leydig cells of the testis.
(05 Mar 2000)
Hurthle cell tumour A neoplasm of the thyroid gland composed of polyhedral acidophilic cells, thought by some to be oncocytes; it may be benign or malignant, the behaviour of the latter depending on the general microscopic pattern, whether follicular, papillary, or undifferentiated.
See: Hurthle cell adenoma.
Synonym: Hurthle cell carcinoma.
(05 Mar 2000)
sertoli cell tumour A rare benign tumour of the testis that histologically resembles the foetal testis. There are three varieties: diffuse stromal, mixed (stromal and epithelial), and tubular (epithelial). Sertoli cells in the epithelial elements may produce oestrogen and cause feminization.
(12 Dec 1998)
sertoli-leydig cell tumour An ovarian tumour usually of low-grade malignancy occurring most frequently in the third and fourth decades, with 75% seen in women under 40. It is rare, representing less than .02% of ovarian cancers. The tumour typically produces androgens with virilization being noted in 70-85% of the patients. (holland et al., cancer medicine, 3d ed, p1684)
(12 Dec 1998)
interstitial cell tumour of testis <tumour> A small benign tumours of the testis that often produce testosterone, causing endocrine symptoms.
Synonym: interstitial cell tumour of testis.
(05 Mar 2000)
ovarian granulosa-theca cell tumour <radiology> Any age, most benign, oestrogens may lead to isosexual precocious puberty (pathognomonic), large tumour with areas of cystic degeneration
(12 Dec 1998)
theca cell tumour A sex cord-stromal tumour of the postmenopausal ovary that is yellow, large, and unilateral, composed of fascicles of lipid-rich spindle cells interspersed with collagen, reticulin fibres, and hyaline plaques. Thecomas and other oestrogen-producing tumours (e.g., granulosa cell tumours) may induce adenomatous hyperplasia of the endometrium or well-differentiated endometrial carcinoma in 3%-20% of the cases.
(12 Dec 1998)
tumour cell <oncology> Cell derived from a tumour in an animal. Refers to a tumour causing malignant cell and not an adventitious normal cell. Loosely, a transformed cell able to give rise to tumours.
(18 Nov 1997)
tumour stem cell assay <investigation> A cytologic technique for measuring the functional capacity of tumour stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agent.
(12 Dec 1998)
leydig cell tumour The most common nongerminal tumour of the testis, derived from the leydig cells. It is rarely malignant. This tumour appears among 1-3% of testicular tumours and although they may be seen in children, the median age of appearance is 60 years. They are sometimes seen in women as ovarian tumours. Clinically, symptoms are usually related to the endocrine abnormalities induced by this tumour.
(12 Dec 1998)
cancer, malignant melanoma A skin cancer that begins in cells called melanocytes that can grow together to form benign (not cancerous) moles. A change in size, shape, or colour of a mole can be a sign of melanoma. Melanoma can be cured if detected early, before spread (metastasis) to other areas of the body. Diagnosis is confirmed with a biopsy of the abnormal skin. Sun exposure can cause skin damage that can lead to melanoma.
(12 Dec 1998)
canine malignant lymphoma <tumour> A progressive fatal disease of dogs characterised by neoplastic transformation and proliferation of lymphoid cells, usually originating in solid lymphoid organs (lymphosarcoma) or bone marrow (lymphocytic leukaemia).
(05 Mar 2000)
malignant <oncology> Tending to become progressively worse and to result in death. Having the properties of anaplasia, invasion and metastasis, said of tumours.
Origin: L. Malignans = acting maliciously
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cadmium cell
    Ä«µå¹Å ÀüÁö
  • cell
    ÀÛÀº¹æ;¾ÏÀÚ(¼öµµ¿ø ºÎ¼ÓÀÇ);»ç½Ç;¿ÀµÎ¸·Áý;¹«´ý;(±³µµ¼ÒÀÇ)µ¶¹æ;(¹úÁýÀÇ)±¸¸Û;²É°¡·çÁÖ¸Ó´Ï;ÀüÁö;¼¼Æ÷;(Á¶Á÷³»ÀÇ)ÀÛÀº °øµ¿;¼¼Æ÷(°ø»ê´ç µîÀÇ);°¡½ºÅë(±â±¸ÀÇ);ºñÆ®ÀÇ ±â¾ï¼ÒÀÚ;µ¶¹æ»ìÀÌÇÏ´Ù;ÀÛÀº ¹æ¿¡ Ʋ¾î¹ÚÈ÷´Ù
  • cell body
    ¼¼Æ÷ÀÇ
  • cell cycle
    ¼¼Æ÷ÁÖ±â;ºÐ¿­ÁÖ±â
  • cell division
    ¼¼Æ÷ºÐ¿­
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • cell lysis
    ¼¼Æ÷¿ëÇØ
  • cell membrane
    ¼¼Æ÷¸·;¿øÇüÁú¸·;=CELL WALL
  • cell sorter
    ¼¼Æ÷ ºÐº°±â
  • cell therapy
    ¼¼Æ÷¿ä¹ý(¾çÀÇ °«³­»õ³¢ÀÇ ¼¼Æ÷¸¦ ÁÖÀÔÇϴ ȸÃá¹ý ('
  • cell wall
    ¼¼Æ÷º®
  • cell-mediated immunity
    ¼¼Æ÷(¸Å°³)¼º ¸é¿ª(¼¼Æ÷¸·¿¡ ºÎÂøÇÏ´Â Ç×üÀÇ Á߻꿡 ÀÇÇÑ
  • closed-cell
    µ¶¸³±âÆ÷ÀÇ;¹ÐÆó±âÆ÷ÀÇ(¼ÒÀç´Â ÇÃ¶ó½ºÆ½µî)
  • complementary cell
    º¸Á· ¼¼Æ÷
  • condemned cell (ward)
    »çÇü¼ö °¨¹æ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á